Free Access
Med Sci (Paris)
Volume 24, Number 2, Février 2008
Page(s) 177 - 184
Section M/S revues
Published online 15 February 2008
  1. Breyer RM, Bagdassarian CK, Myers SA, Breyer MD. Prostanoid receptors : subtypes and signaling. Annu Rev Pharmacol Toxicol 2001; 41 : 661–90. [Google Scholar]
  2. Hata AN, Breyer RM. Pharmacology and signaling of prostaglandin receptors : multiple roles in inflammation and immune modulation. Pharmacol Ther 2004; 103 : 147–66. [Google Scholar]
  3. Urade Y, Hayaishi O. Biochemical, structural, genetic, physiological, and pathophysiological features of lipocalin-type prostaglandin D synthase. Biochim Biophys Acta 2000; 1482 : 259–71. [Google Scholar]
  4. Herlong JL, Scott TR. Positioning prostanoids of the D and J series in the immunopathogenic scheme. Immunol Lett 2006; 102 : 121–31. [Google Scholar]
  5. Kanaoka Y, Fujimori K, Kikuno R, et al. Structure and chromosomal localization of human and mouse genes for hematopoietic prostaglandin D synthase. Conservation of the ancestral genomic structure of sigma-class glutathione S-transferase. Eur J Biochem 2000; 267 : 3315–22. [Google Scholar]
  6. Tanaka K, Ogawa K, Sugamura K, et al. Cutting edge : differential production of prostaglandin D2 by human helper T cell subsets. J Immunol 2000; 164 : 2277–80. [Google Scholar]
  7. Urade Y, Hayaishi O. Prostaglandin D synthase : structure and function. Vitam Horm 2000; 58 : 89–120. [Google Scholar]
  8. Ueno N, Takegoshi Y, Kamei D, et al. Coupling between cyclooxygenases and terminal prostanoid synthases. Biochem Biophys Res Commun 2005; 338 : 70–6. [Google Scholar]
  9. Morita I. Distinct functions of COX-1 and COX-2. Prostaglandins Other Lipid Mediat 2002; 68-69 : 165–75. [Google Scholar]
  10. Loftin CD, Tiano HF, Langenbach R. Phenotypes of the COX-deficient mice indicate physiological and pathophysiological roles for COX-1 and COX-2. Prostaglandins Other Lipid Mediat 2002; 68-69 : 177–85. [Google Scholar]
  11. Fujimori K, Kadoyama K, Urade Y. Protein kinase C activates human lipocalin-type prostaglandin D synthase gene expression through de-repression of notch-HES signaling and enhancement of AP-2 beta function in brain-derived TE671 cells. J Biol Chem 2005; 280 : 18452–61. [Google Scholar]
  12. Mong JA, Devidze N, Frail DE, et al. Estradiol differentially regulates lipocalin-type prostaglandin D synthase transcript levels in the rodent brain : evidence from high-density oligonucleotide arrays and in situ hybridization. Proc Natl Acad Sci USA 2003; 100 : 318–23. [Google Scholar]
  13. Li L, Yang Y, Stevens RL. RasGRP4 regulates the expression of prostaglandin D2 in human and rat mast cell lines. J Biol Chem 2003; 278 : 4725–9. [Google Scholar]
  14. Samy ET, Li JC, Grima J, et al. Sertoli cell prostaglandin D2 synthetase is a multifunctional molecule : its expression and regulation. Endocrinology 2000; 141 : 710–21. [Google Scholar]
  15. Boie Y, Sawyer N, Slipetz DM, et al. Molecular cloning and characterization of the human prostanoid DP receptor. J Biol Chem 1995; 270 : 18910–6. [Google Scholar]
  16. Hirai H, Tanaka K, Yoshie O, et al. Prostaglandin D2 selectively induces chemotaxis in T helper type 2 cells, eosinophils, and basophils via seven-transmembrane receptor CRTH2. J Exp Med 2001; 193 : 255–61. [Google Scholar]
  17. Kobayashi T, Narumiya S. Function of prostanoid receptors : studies on knockout mice. Prostaglandins Other Lipid Mediat 2002; 68-69 : 557–73. [Google Scholar]
  18. Pinzar E, Kanaoka Y, Inui T, et al. Prostaglandin D synthase gene is involved in the regulation of non-rapid eye movement sleep. Proc Natl Acad Sci USA 2000; 97 : 4903–7. [Google Scholar]
  19. Huang ZL, Urade Y, Hayaishi O. Prostaglandins and adenosine in the regulation of sleep and wakefulness. Curr Opin Pharmacol 2007; 7 : 33–8. [Google Scholar]
  20. Rolin S, Masereel B, Dogne JM. Prostanoids as pharmacological targets in COPD and asthma. Eur J Pharmacol 2006; 533 : 89–100. [Google Scholar]
  21. Matsuoka T, Hirata M, Tanaka H, et al. Prostaglandin D2 as a mediator of allergic asthma. Science 2000; 287 : 2013–7. [Google Scholar]
  22. Pettipher R, Hansel TT, Armer R. Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases. Nat Rev Drug Discov 2007; 6 : 313–25. [Google Scholar]
  23. Kostenis E, Ulven T. Emerging roles of DP and CRTH2 in allergic inflammation. Trends Mol Med 2006; 12 : 148–58. [Google Scholar]
  24. Schuligoi R, Grill M, Heinemann A, et al. Sequential induction of prostaglandin E and D synthases in inflammation. Biochem Biophys Res Commun 2005; 335 : 684–9. [Google Scholar]
  25. Kobayashi T, Narumiya S. Prostanoids in health and disease ; lessons from receptor-knockout mice. Adv Exp Med Biol 2002; 507 : 593–7. [Google Scholar]
  26. Hasumoto K, Sugimoto Y, Yamasaki A, et al. Association of expression of mRNA encoding the PGF2 alpha receptor with luteal cell apoptosis in ovaries of pseudopregnant mice. J Reprod Fertil 1997; 109 : 45–51. [Google Scholar]
  27. Lumsden MA, Kelly RW, Templeton AA, et al. Changes in the concentration of prostaglandins in preovulatory human follicles after administration of hCG. J Reprod Fertil 1986; 77 : 119–24. [Google Scholar]
  28. Schell C, Frungieri MB, Albrecht M, et al. A Prostaglandin D2 system in the human testis. Fertil Steril 2007; 88 : 233–6. [Google Scholar]
  29. Cheuk BL, Chew SB, Fiscus RR, Wong PY. Cyclooxygenase-2 regulates apoptosis in rat epididymis through prostaglandin D2. Biol Reprod 2002; 66 : 374–80. [Google Scholar]
  30. Saito S, Tsuda H, Michimata T. Prostaglandin D2 and reproduction. Am J Reprod Immunol 2002; 47 : 295–302. [Google Scholar]
  31. Wilhelm D, Martinson F, Bradford S, et al. Sertoli cell differentiation is induced both cell-autonomously and through prostaglandin signaling during mammalian sex determination. Dev Biol 2005; 287 : 111–24. [Google Scholar]
  32. Wilhelm D, Hiramatsu R, Mizusaki H, et al. SOX9 regulates prostaglandin D synthase gene transcription in vivo to ensure testis development. J Biol Chem 2007; 282 : 10553–60. [Google Scholar]
  33. Malki S, Nef S, Notarnicola C, et al. Prostaglandin D2 induces nuclear import of the sex-determining factor SOX9 via its cAMP-PKA phosphorylation. EMBO J 2005; 24 : 1798–809. [Google Scholar]
  34. Nef S, Schaad O, Stallings NR, et al. Gene expression during sex determination reveals a robust female genetic program at the onset of ovarian development. Dev Biol 2005; 287 : 361–77. [Google Scholar]
  35. Vidal VP, Chaboissier MC, de Rooij DG, Schedl A. Sox9 induces testis development in XX transgenic mice. Nat Genet 2001; 28 : 216–7. [Google Scholar]
  36. Barrionuevo F, Bagheri-Fam S, Klattig J, et al. Homozygous inactivation of Sox9 causes complete XY sex reversal in mice. Biol Reprod 2006; 74 : 195–201. [Google Scholar]
  37. Morais da Silva S, Hacker A, Harley V, et al. Sox9 expression during gonadal development implies a conserved role for the gene in testis differentiation in mammals and birds. Nat Genet 1996; 14 : 62–8. [Google Scholar]
  38. Gasca S, Canizares J, De Santa Barbara P, et al. A nuclear export signal within the high mobility group domain regulates the nucleocytoplasmic translocation of SOX9 during sexual determination. Proc Natl Acad Sci USA 2002; 99 : 11199–204. [Google Scholar]
  39. Malki S, Berta P, Poulat F, Boizet-Bonhoure B. Cytoplasmic retention of the sex-determining factor SOX9 via the microtubule network. Exp Cell Res 2005; 309 : 468–75. [Google Scholar]
  40. Kim Y, Kobayashi A, Sekido R, et al. Fgf9 and wnt4 act as antagonistic signals to regulate Mammalian sex determination. PLoS Biol 2006; 4 : e187. [Google Scholar]
  41. Pujol P, Rey JM, Nirde P, et al. Differential expression of estrogen receptor-alpha and -beta messenger RNAs as a potential marker of ovarian carcinogenesis. Cancer Res 1998; 58 : 5367–73. [Google Scholar]
  42. Munkarah AR, Morris R, Baumann P, et al. Effects of prostaglandin E(2) on proliferation and apoptosis of epithelial ovarian cancer cells. J Soc Gynecol Investig 2002; 9 : 168–73. [Google Scholar]
  43. Denkert C, Kobel M, Pest S, et al. Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol 2002; 160 : 893–903. [Google Scholar]
  44. Daikoku T, Wang D, Tranguch S, et al. Cyclooxygenase-1 is a potential target for prevention and treatment of ovarian epithelial cancer. Cancer Res 2005; 65 : 3735–44. [Google Scholar]
  45. Malki S, Bibeau F, Notarnicola C, et al. Expression and biological role of the prostaglandin D synthase/SOX9 pathway in human ovarian cancer cells. Cancer Lett 2007; 255 : 182–93 [Google Scholar]
  46. Kikuchi Y, Kita T, Miyauchi M, et al. Inhibition of human ovarian cancer cell proliferation in vitro by neuroendocrine hormones. Gynecol Oncol 1989; 32 : 60–4. [Google Scholar]
  47. Kikuchi Y, Miyauchi M, Iwano I, et al. Adjuvant effects of prostaglandin D2 to cisplatin on human ovarian cancer cell growth in nude mice. Eur J Cancer Clin Oncol 1988; 24 : 1829–33. [Google Scholar]
  48. Su B, Guan M, Xia J, Lu Y. Stimulation of lipocalin-type prostaglandin D synthase by retinoic acid coincides with inhibition of cell proliferation in human 3AO ovarian cancer cells. Cell Biol Int 2003; 27 : 587–92. [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.